Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AtriCure, Inc. - Common Stock (NQ: ATRC )

32.76 +0.07 (+0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ: 
Via Benzinga
AtriCure, inc (ATRC) Q2 2021 Earnings Call Transcript
ATRC earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AtriCure Reports Second Quarter 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
Earnings Scheduled For April 27, 2021
Companies Reporting Before The Bell • Camden National (NASDAQ:CAC) is projected to report quarterly earnings at $1.01 per share on revenue of $45.73 million. •... 
Via Benzinga
Stocks That Hit 52-Week Highs On Friday
On Friday morning, 152 companies hit new 52-week highs. Things to Consider: The largest company by market cap to hit a new 52-week high was ASML Holding (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
AtriCure to Announce Second Quarter 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
AtriCure Names Two New Members to the Board of Directors
From AtriCure, Inc.
Via Business Wire
Expert Ratings for AtriCure
Analysts have provided the following ratings for AtriCure (NASDAQ:ATRC) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2 0 0... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Morgan Stanley boosted the price target for Intuit Inc. (NASDAQ: INTU) from $470 to $511. Intuit shares rose 1% to $443.50 in pre-market trading. Keybanc raised the price target... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock rose 21.78% to $8.05 during Thursday's regular session. As of 12:32 EST, Galera Therapeutics's stock is trading at... 
Via Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
From AtriCure, Inc.
Via Business Wire
65 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs. Takung Art Co., Ltd. (... 
Via Benzinga
Here's Why AtriCure Stock Is Moving Today
AtriCure Inc. (NASDAQ: ATRC) shares are trading higher by 6.35% at $69.03 after the company reported better-than-expected first-quarter EPS and sales results. Oppenheimer analyst... 
Via Benzinga
54 Stocks Moving In Thursday's Mid-Day Session
Gainers Willamette Valley Vineyards, Inc. (NASDAQ: WVVI) climbed 40.5% to $14.39. Dolphin Entertainment, Inc. (NASDAQ: DLPN) shares gained 23.1% to $14.14. Dolphin Entertainment... 
Via Benzinga
AtriCure Inc (ATRC) Q1 2021 Earnings Call Transcript
ATRC earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AtriCure: Q1 Earnings Insights
Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 11.11% year over year... 
Via Benzinga
AtriCure Reports First Quarter 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Preview: AtriCure's Earnings
AtriCure (NASDAQ:ATRC) announces its next round of earnings this Tuesday, April 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings... 
Via Benzinga
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback